Produktname:2,5-Dichloro-4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl)pyrimidine
IUPAC Name:2,5-dichloro-4-[5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl]pyrimidine
- CAS:2079069-47-7
- Molekulare Formel:C12H12Cl2N4
- Reinheit:95%+
- Katalognummer:CM1077692
- Molekulargewicht:283.16
Packungseinheit |
Verfügbarer Vorrat |
Preis($) |
Menge |
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:2079069-47-7
- Molekulare Formel:C12H12Cl2N4
- Schmelzpunkt:-
- SMILES-Code:ClC1=NC=C(Cl)C(=N1)C=2C=NN(C2CC3CC3)C
- Dichte:1.54±0.1 g/cm3
- Katalognummer:CM1077692
- Molekulargewicht:283.16
- Siedepunkt:477.0±45.0 °C
- Mdl-Nr.:
- Lagerung:
Category Infos
- Pyrazoles
- Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
- Pyrazone
- Custom pyrazone for customers from all over the world are our main business.
- Pyrimidines
- Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Column Infos
- BTX-A51
- Edgewood Oncology announced that the first two patients with metastatic breast cancer were treated with BTX-A51, a multi-specific kinase inhibitor of casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), that synergistically targets master regulators of cancer. BTX-A51 is being evaluated in a Phase 2a study for the treatment of estrogen receptor positive / human epidermal growth factor receptor 2 negative (ER+/HER2-) metastatic breast cancer with and without GATA binding protein 3 (GATA3) mutations.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.